PARP Inhibitors in 2020: Where Are We Now, and Where Are We Going? with Payal D. Shah, MD

• In this webinar, we will review the mechanism of action of PARP inhibitors including the principle of synthetic lethality and the cellular basis for PARP inhibitor activity.  We will then review some of the seminal clinical trials leading to FDA approval of PARP inhibitors in the context of ovarian cancer, metastatic breast cancer, and pancreas cancer.  Finally, we will discuss select clinical trials representative of directions of future PARP inhibitor development.

  

  Only the live session qualifies for CEUs but when possible, we host the recordings on our website and NSGC recommends participants to use their personal email instead of work email addresses to ensure they receive their CEU certificates.

  

  Ambry Genetics is approved as a provider for continuing education program by NSGC and ASCLS P.A.C.E ® Program.

Payal D. Shah, MD | Presenter

Assistant Professor of Medicine, University of Pennsylvania

Dr. Payal Shah is an Assistant Professor of Medicine in at the Basser Center for BRCA and the Abramson Cancer Center at the University of Pennsylvania.  She is a medical oncologist and clinical investigator specializing in breast cancer and cancer genetics and conducts clinical trials examining targeted therapy and immunotherapy.  She is the recipient of several awards including a Susan G. Komen Career Catalyst Award and an ASCO Conquer Cancer Foundation Young Investigator Award.

Brissa Martin, MS, CGC | Moderator

Sr. Manager, Reporting- Rare Disease, Ambry Genetics

Brissa Martin received her B.S. in Microbiology and Molecular Genetics from the University of California, Los Angeles and her M.S. in Genetic Counseling from the University of California, Irvine. She has worked primarily in the field of molecular diagnostics and has experience in a variety of specialties including neurology, mitochondrial and metabolic disorders, cancer, and whole exome sequencing. She has clinical expertise in pediatric genetics and prenatal diagnosis. Additional experience includes laboratory processes, result reporting, variant assessment, test launching, client services, and sales.